Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Bausch Health Companies Inc.

https://www.bauschhealth.com/

Latest From Bausch Health Companies Inc.

Amgen Gets Into Position For MariTide Development

In an interview, CFO Peter Griffith pointed to a boost in capex to build out capacity for the obesity drug, which the company expects to move into Phase III development in the near term.

Sales & Earnings Business Strategies

Sun Seeks Partner For GLP-I Asset, Legal Challenge Clouds Alopecia Drug Launch

Sun’s chief Dilip Shanghvi talks about partnering intent for the firm’s GLP-1 candidate, which he hopes can complete studies in an accelerated timeframe, while legal action in the US has a cast a shadow on launch timelines of the Indian drug maker's alopecia areata treatment.

Commercial Research & Development

Rejuvenated A Year Into Saunders’ Return To Helm, B+L Refreshing Blink, Lumify Lines

Brimonidine tartrate eye drops remain key sales driver among Canadian firm’s consumer health lines with 12% growth in the latest quarter. B+L expects pending launch of preservative-free line extension to sustain Lumify as a driver as generics of original formulation are approved.

Dietary Supplements OTC Drugs

Viking Plans To Go Directly To Phase III With Obesity Drug

In its Q2 earnings call, the biotech expressed optimism about developing VK2735 as a monthly injection, with an oral version moving into Phase II. An EOP2 meeting for its MASH drug is expected in Q4.

Sales & Earnings Metabolic Disorders
See All

Company Information

  • Industry
  • Medical Devices
  • Pharmaceuticals
  • Pharmaceuticals
    • Generic Drugs
    • OTC, Consumer
  • Medical Devices
    • Implantable Devices
    • Surgical Equipment & Devices
  • Other Names / Subsidiaries
    • AB Sanitas
    • Afexa Life Sciences Inc.
    • Amoun Pharmaceutical
    • Aton Pharma, Inc.
    • Bausch Health Ireland Limited
    • Bausch + Lomb Holding International
    • Biovail Corporation
    • Callisto Pharmaceuticals, Inc. Dendreon Corporation
    • Dermik Laboratories, Inc.
    • Dow Pharmaceutical Sciences, Inc.
    • Eyetech Inc.
    • Graceway Pharmaceuticals, LLC
    • ICN Pharmaceuticals, Inc.
    • iNova Diagnostics, Inc.
    • Instituto Terapeutico Delta Ltda
    • Medicis Aesthetics Holdings Inc
    • Medicis Pharmaceutical Corporation
    • Mercury (Cayman) Holdings
    • OraPharma, Inc.
    • Ortho Dermatologics
    • Prestwick Pharmaceuticals, Inc.
    • PharmaSwiss S.A.
    • Pedinol Pharmacal, Inc.
    • Salix Pharmaceuticals Ltd. (InKine Pharmaceutical
    • Oceana Therapeutics, LLC
    • Q-Med Scandinavia, Inc.
    • Santarus, Inc.)
    • Sanitas AB
    • Solta Medical, Inc.
    • SPI Pharmaceuticals Inc
    • Synergetics USA, Inc.
    • Synergy Pharmaceuticals Inc.(SGYP)
    • Technolas Perfect Vision GmbH (TPV)
    • Ucyclyd Pharma, Inc.
    • Unilens Vision, Inc.
    • Viratek Pharma Inc
    • Valeant Pharmaceuticals International, Inc.
    • Xcel Pharmaceuticals, Inc.
UsernamePublicRestriction

Register